Aurobindo Pharma has informed that it enclosed details of investor meeting on 23-02-2023. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. This intimation is submitted pursuant to Regulation 30(6) of the Listing Regulations.
The above information is a part of company’s filings submitted to BSE.